Germany’s Bayer AG will acquire Yunnan-based Dihon Pharmaceutical Co. Ltd., the National Business Daily reported Friday. The deal, pending approvals from regulators, is expected to be completed in the second half of this year, Bayer was quoted as saying without providing financial details. The paper cited a source as saying that the deal could be worth about 3.6 billion yuan (US$590.2 million). Olivier Brandicourt, chief executive of Bayer, was quoted as saying that the deal will help Bayer’s expansion in China, especially in the traditional Chinese medicine market.
– Contact HKEJ at [email protected]